At ITbM, Nagoya University, researchers developed a new nickel catalyst with a "Kabuto-like" structure.
It was found to catalyze the cross-coupling reaction between carbonyl compounds and readily available phenol derivatives, to form alpha-arylketones, which are found in many biologically active compounds (Kabuto = a helmet worn by Japanese samurai).
Chemists Designed New Class of Catalysts Triggered by Single Proton
At Boston College, chemists have designed a new class of catalysts triggered by the charge of a single proton.
Advertisement
Nagoya, Japan - Professors Kenichiro Itami and Junichiro Yamaguchi of the Institute of Transformative Bio-Molecules (WPI-ITbM) and graduate students Ryosuke Takise and Kei Muto of Nagoya University have succeeded in developing a novel nickel catalyst to catalyze the cross-coupling reaction between carbonyl compounds and phenol derivatives.
Phenol derivatives are known to be readily available starting materials, and this reaction has enabled the facile generation of alpha-arylketone compounds (aryl = aromatic ring; ketone = a carbonyl (C=O functionality with a carbon oxygen double bond) bonded to two other carbon atoms), which constitute the framework of many pharmaceuticals and organic materials. The study published online on May 20, 2014 in Angewandte Chemie International Edition, is expected to become an important tool in synthesizing biologically active molecules and a range of versatile organic materials containing the alpha-arylketone framework.
![Using Small Amount of Catalysts Has No Negative Effects in Manufacturing Pharmaceuticals]( "Using Small Amount of Catalysts Has No Negative Effects in Manufacturing Pharmaceuticals")
Researchers at University of Gothenburg have demonstrated that using small amounts of catalysts, copper in this case, can work well in manufacture of pharmaceuticals.
Cross-coupling reactions catalyzed by transition metals enables direct formation of carbon-carbon bonds, which is widely utilized in the formation of a vast number of organic frameworks. This strategy that won the 2010 Nobel Prize in Chemistry extends to alpha-arylation reactions, which allows incorporation of aromatic rings into carbonyl compounds through carbon-carbon bond formation, mainly using palladium as a catalyst. Many organic molecules such as amino acids contain carbonyl groups. Thus, alpha-arylation, which links carbonyl compounds to aromatic rings present in an array of organic molecules, has been used as one of the main reactions to create the organic backbone of many pharmaceuticals and organic materials.
Professors Itami and Yamaguchi along with co-workers have been working to develop a new economical catalyst to conduct alpha-arylation reactions using readily available phenol derivatives as starting materials. This reaction system is envisaged to lead to the facile production of alpha-arylketones on an industrial scale.
Source: Eurekalert
Using Small Amount of Catalysts Has No Negative Effects in Manufacturing Pharmaceuticals
Researchers at University of Gothenburg have demonstrated that using small amounts of catalysts, copper in this case, can work well in manufacture of pharmaceuticals.
Advertisement
Cross-coupling reactions catalyzed by transition metals enables direct formation of carbon-carbon bonds, which is widely utilized in the formation of a vast number of organic frameworks. This strategy that won the 2010 Nobel Prize in Chemistry extends to alpha-arylation reactions, which allows incorporation of aromatic rings into carbonyl compounds through carbon-carbon bond formation, mainly using palladium as a catalyst. Many organic molecules such as amino acids contain carbonyl groups. Thus, alpha-arylation, which links carbonyl compounds to aromatic rings present in an array of organic molecules, has been used as one of the main reactions to create the organic backbone of many pharmaceuticals and organic materials.
Professors Itami and Yamaguchi along with co-workers have been working to develop a new economical catalyst to conduct alpha-arylation reactions using readily available phenol derivatives as starting materials. This reaction system is envisaged to lead to the facile production of alpha-arylketones on an industrial scale.
Source: Eurekalert
Novel Catalysts Promise Cheaper, Greener Drugs
Environmentally-friendly iron-based nanoparticle catalysts promise the synthesis of greener and cheaper drugs, say chemists.
Advertisement
 Stem Cells may Act as Catalyst for Hepatitis ResearchHepatitis C is a mysterious disease as it has different effects on different people. | Advertisement
|
Advertisement
Latest Research News
The AI method shows promise in identifying imaging biomarkers for diagnosing ADHD.
Diagnosed autistic individuals showed increased premature mortality in the UK, highlighting urgent needs to address associated inequalities.
Study reveals a correlation between hearing impairment and distinct brain region variances, contributing to dementia.
Financial impact of caring for individuals with neurodegenerative disorders reaches hundreds of billions annually in the United States.
Experts emphasize that addressing the skills gap demands immediate attention and innovative solutions, including education, re-training, and significant time investment.